secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-08-03T10:50:04+00:00
Accession:  0001193125-26-329520
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior Q2 revenue $343M (+14% YoY), raises FY2026 guidance; merger with Supernus expected Q4
--------------------------------------------------------------------------------

- Q2 GAAP net income $122M ($0.98 diluted EPS) vs $18M ($0.14) YoY; Non-GAAP net income $142M ($1.15).
- Record SUBLOCADE net revenue $253M (+21% YoY); new patient starts of 32,816 were a record.
- FY2026 guidance raised: total net revenue $1,295M-$1,365M; adjusted EBITDA $700M-$740M (midpoint +68% YoY).
- Repurchased 4.7M shares for $175M in Q2; year-to-date $300M in buybacks.
- Announced all-stock merger of equals with Supernus; expected close in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/0001193125-26-329520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-329520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer